These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35214156)

  • 1. Interaction and Compatibility Studies in the Development of Olmesartan Medoxomil and Hydrochlorothiazide Formulations under a Real Manufacturing Process.
    Murillo-Fernández MA; Montero-Zeledón E; Abdala-Saiz A; Vega-Baudrit JR; Araya-Sibaja AM
    Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Co-Crystallization of Olmesartan Medoxomil and Hydrochlorothiazide for Enhanced Dissolution Rate in Their Fixed Dose Combination.
    Abdelquader MM; Essa EA; El Maghraby GM
    AAPS PharmSciTech; 2018 Dec; 20(1):3. PubMed ID: 30560314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability Enhancement of Olmesartan Medoxomil Using Hot-Melt Extrusion: In-Silico, In-Vitro, and In-Vivo Evaluation.
    Jadhav P; Gokarna V; Deshpande V; Vavia P
    AAPS PharmSciTech; 2020 Sep; 21(7):254. PubMed ID: 32888102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ratio spectra derivative and zero-crossing difference spectrophotometric determination of olmesartan medoxomil and hydrochlorothiazide in combined pharmaceutical dosage form.
    Rote AR; Bari PD
    AAPS PharmSciTech; 2009; 10(4):1200-5. PubMed ID: 19862625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compatibility study between ketoprofen and pharmaceutical excipients used in solid dosage forms.
    Tiţa B; Fuliaş A; Bandur G; Marian E; Tiţa D
    J Pharm Biomed Anal; 2011 Sep; 56(2):221-7. PubMed ID: 21665404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-way analysis of the UPLC-PDA dataset for the multicomponent quantitation of hydrochlorothiazide and olmesartan medoxomil in tablets by parallel factor analysis and three-way partial least squares.
    Dinç E; Ertekin ZC
    Talanta; 2016; 148():144-52. PubMed ID: 26653435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on compatibility assessment of empagliflozin with the selected pharmaceutical excipients employed in solid dosage forms by thermal, spectroscopic and chromatographic techniques.
    Niguram P; Polaka SN; Rathod R; Kalia K; Kate AS
    Drug Dev Ind Pharm; 2020 Feb; 46(2):209-218. PubMed ID: 31933394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanostructured lipid carriers of olmesartan medoxomil with enhanced oral bioavailability.
    Kaithwas V; Dora CP; Kushwah V; Jain S
    Colloids Surf B Biointerfaces; 2017 Jun; 154():10-20. PubMed ID: 28284054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of a stability-indicating UPLC method for the determination of olmesartan medoxomil, amlodipine and hydrochlorothiazide degradation impurities in their triple-combination dosage form using factorial design of experiments.
    Marisetti VM; Katakam P; Siddhani VK; Katari NK
    Biomed Chromatogr; 2021 Nov; 35(11):e5194. PubMed ID: 34110035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In Vitro and In Vivo Evaluation of Olmesartan Medoxomil Microcrysta ls and Nanocrystals: Preparation, Characterization, and Pharmacokinet ic Comparison in Beagle Dogs.
    Chai R; Gao H; Ma Z; Guo M; Fu Q; Liu H; He Z
    Curr Drug Deliv; 2019; 16(6):500-510. PubMed ID: 31244438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a population pharmacokinetic model to describe olmesartan medoxomil/ hydrochlorothiazide (20/12.5 mg) FDC tablet in male healthy South Korean subjects.
    Chae JW; Baek IH; Seo JW; Jung SH; Back HM; Song BJ; Lee BY; Yun HY; Kang W; Kwon KI
    Int J Clin Pharmacol Ther; 2014 Aug; 52(8):676-83. PubMed ID: 24849193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of long-term safety of fixed-dose combinations azilsartan medoxomil/chlorthalidone vs olmesartan medoxomil/hydrochlorothiazide.
    Neutel JM; Cushman WC; Lloyd E; Barger B; Handley A
    J Clin Hypertens (Greenwich); 2017 Sep; 19(9):874-883. PubMed ID: 28681550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risperidone/Randomly Methylated β-Cyclodextrin Inclusion Complex-Compatibility Study with Pharmaceutical Excipients.
    Sbârcea L; Tănase IM; Ledeți A; Cîrcioban D; Vlase G; Barvinschi P; Miclău M; Văruţ RM; Suciu O; Ledeți I
    Molecules; 2021 Mar; 26(6):. PubMed ID: 33802960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combination in healthy subjects.
    Kreutz R; Bolbrinker J; Huber M
    Clin Drug Investig; 2006; 26(1):29-34. PubMed ID: 17163232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulation, optimization, and in vitro-in vivo evaluation of olmesartan medoxomil nanocrystals.
    Jain S; Patel K; Arora S; Reddy VA; Dora CP
    Drug Deliv Transl Res; 2017 Apr; 7(2):292-303. PubMed ID: 28116656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of Compatibility Between Polymeric Excipients and Atenolol Using Principal Component Analysis and Hierarchical Cluster Analysis.
    Rojek B; Gazda M; Wesolowski M
    AAPS PharmSciTech; 2021 Nov; 23(1):3. PubMed ID: 34799781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solid lipid nanoparticles as vesicles for oral delivery of olmesartan medoxomil: formulation, optimization and in vivo evaluation.
    Nooli M; Chella N; Kulhari H; Shastri NR; Sistla R
    Drug Dev Ind Pharm; 2017 Apr; 43(4):611-617. PubMed ID: 28005442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement.
    Thakkar HP; Patel BV; Thakkar SP
    J Pharm Bioallied Sci; 2011 Jul; 3(3):426-34. PubMed ID: 21966165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissolution stability studies of suspensions of prolonged-release diclofenac microcapsules prepared by the Wurster process: I. Eudragit-based formulation and possible drug-excipient interaction.
    Adeyeye MC; Mwangi E; Katondo B; Jain A; Ichikawa H; Fukumori Y
    J Microencapsul; 2005 Jun; 22(4):333-42. PubMed ID: 16214782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
    Barrios V; Boccanelli A; Ewald S; Girerd X; Heagerty A; Krzesinski JM; Lins R; Rodicio J; Stefenelli T; Woittiez A; Böhm M
    Clin Drug Investig; 2007; 27(8):545-58. PubMed ID: 17638395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.